Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L L Ross

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2000
Parsing executive processes: strategic vs. evaluative functions of the anterior cingulate cortexC S Carter, A M Macdonald, M Botvinick, et al.
Experimental Eye Research|October 1, 1995
Coordinated activation of corneal wound response genes in vivo as observed by in situ hybridizationL L Ross, S C Danehower, A D Proia, et al.
The Journal of Antimicrobial Chemotherapy|December 17, 2009
Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovirL L Ross, E Rouse, P Gerondelis, et al.
The Journal of Infectious Diseases|February 15, 2001
Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET StudyK Henry, R J Wallace, P C Bellman, et al.
Journal of Clinical Microbiology|September 17, 1999
Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudineM I Allen, J Gauthier, M DesLauriers, et al.
HIV Medicine|July 16, 2015
The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavirD A Wohl, L Bhatti, C B Small, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2000
Parsing executive processes: strategic vs. evaluative functions of the anterior cingulate cortexC S Carter, A M Macdonald, M Botvinick, et al.
Experimental Eye Research|October 1, 1995
Coordinated activation of corneal wound response genes in vivo as observed by in situ hybridizationL L Ross, S C Danehower, A D Proia, et al.
The Journal of Antimicrobial Chemotherapy|December 17, 2009
Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovirL L Ross, E Rouse, P Gerondelis, et al.
The Journal of Infectious Diseases|February 15, 2001
Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET StudyK Henry, R J Wallace, P C Bellman, et al.
Journal of Clinical Microbiology|September 17, 1999
Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudineM I Allen, J Gauthier, M DesLauriers, et al.
HIV Medicine|July 16, 2015
The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavirD A Wohl, L Bhatti, C B Small, et al.
Pageof 4